Editorial: Novel therapeutic targets in autoimmune diseases: intestinal microbiota and adaptive immunity regulation

The authors declare that no Generative AI was used in the creation of this manuscript. 16Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers 17 with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, 18 including review by the authors wherever possible. If you identify any issues, please contact us. 19All claims expressed in this article are solely those of the authors and do not necessarily represent those 21 of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product 22 that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed 23 or endorsed by the publisher. 24Autoimmune diseases comprise more than 80 different diseases and affect an increasing 25 number of people, with women between the ages of 20 and 40 being the most affected. Autoimmune 26 diseases are a significant burden on the healthcare system and are characterized by the presence of 27 autoreactive T lymphocytes or autoantibodies, which may be physiologically or pathologically 28 induced.